Results 281 to 290 of about 387,299 (303)

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet, 2019
BACKGROUND Non-alcoholic steatohepatitis (NASH) is characterised by hepatic steatosis, inflammation, hepatocellular injury, and progressive liver fibrosis.
S. Harrison, M. Bashir, Cynthia D. Guy, R. Zhou, Cynthia A. Moylan, J. Frias, N. Alkhouri, M. Bansal, S. Baum, B. Neuschwander‐Tetri, R. Taub, S. Moussa   +11 more
semanticscholar   +1 more source

THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES.

Clinical Gastroenterology and Hepatology
BACKGROUND AND AIMS Nonalcoholic fatty liver disease (NAFLD) now known as metabolic dysfunction associated steatotic liver disease (MASLD) is closely associated with type 2 diabetes (T2D).
Z. Younossi, P. Golabi, J. Price, Soroor Owrangi, Nagashree Gundu-Rao, Romona Satchi, James M. Paik   +6 more
semanticscholar   +1 more source

Non-alcoholic steatohepatitis.

Medicina clínica (Ed. impresa), 2022
Non-alcoholic steatohepatitis belongs to the spectrum of metabolic-associated fatty liver diseases characterized by steatosis linked to obesity, diabetes, metabolic syndrome, dyslipidemia and immune-mediated disorders.
M. Romero-Gómez
semanticscholar   +1 more source

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Nature Medicine, 2021
S. Harrison, P. Ruane, B. Freilich, G. Neff, Rashmee Patil, C. Behling, Chen-bo Hu, Erica Fong, Brittany de Temple, Erik J. Tillman, T. Rolph, Andrew Cheng, Kitty Yale   +12 more
semanticscholar   +1 more source

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.

The Lancet, 2018
BACKGROUND Pegbelfermin (BMS-986036), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previously been shown to improve markers of metabolism and liver fibrosis in obese patients with type 2 diabetes.
A. Sanyal, E. Charles, B. Neuschwander‐Tetri, R. Loomba, S. Harrison, M. Abdelmalek, E. Lawitz, D. Halegoua-DeMarzio, S. Kundu, S. Noviello, Yi Luo, Rose C. Christian   +11 more
semanticscholar   +1 more source

XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis

Nature Medicine, 2021
Aleksandra Deczkowska, Eyal David, P. Ramadori, D. Pfister, M. Safran, Baoguo Li, A. Giladi, Diego Jaitin, O. Barboy, Merav Cohen, Ido Yofe, C. Gur, Shir Shlomi-Loubaton, S. Henri, Yousuf Suhail, Meng-Jie Qiu, S. Kam, H. Hermon, E. Lahat, G. Ben Yakov, O. Cohen-ezra, Y. Davidov, M. Likhter, D. Goitein, S. Roth, A. Weber, B. Malissen, A. Weiner, Z. Ben‐Ari, Mathias F. Heikenwälder, E. Elinav, I. Amit   +31 more
semanticscholar   +1 more source

Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies

Nature Reviews Drug Discovery, 2016
Giovanni Musso, Roberto Gambino, Maurizio Cassader   +2 more
exaly  

How different is the dietary pattern in non-alcoholic steatohepatitis patients?

Clinical Nutrition, 2006
Carla Lopes, Helena Cortez-Pinto, Henrique Barros   +2 more
exaly  

Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice

Journal of Hepatology, 2020
Xiaojing Wang, Kai Huang, Cheng Wang
exaly  

Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis

Journal of Hepatology, 1999
Herbert L Bonkovsky, Barbara F Banner, Richard W Lambrecht   +2 more
exaly